Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Intangibles (2016 - 2025)

Historic Intangibles for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $15.7 million.

  • Anika Therapeutics' Intangibles rose 252266.67% to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year increase of 252266.67%. This contributed to the annual value of $2.5 million for FY2024, which is 8744.71% down from last year.
  • Anika Therapeutics' Intangibles amounted to $15.7 million in Q3 2025, which was up 252266.67% from $15.7 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Intangibles high stood at $112.7 million for Q1 2021, and its period low was $600000.0 during Q3 2024.
  • For the 5-year period, Anika Therapeutics' Intangibles averaged around $74.2 million, with its median value being $112.1 million (2022).
  • Per our database at Business Quant, Anika Therapeutics' Intangibles tumbled by 9946.49% in 2024 and then soared by 252266.67% in 2025.
  • Over the past 5 years, Anika Therapeutics' Intangibles (Quarter) stood at $112.7 million in 2021, then dropped by 0.53% to $112.1 million in 2022, then crashed by 82.31% to $19.8 million in 2023, then crashed by 87.45% to $2.5 million in 2024, then surged by 531.97% to $15.7 million in 2025.
  • Its Intangibles stands at $15.7 million for Q3 2025, versus $15.7 million for Q2 2025 and $20.4 million for Q1 2025.